Oxeia Biopharmaceuticals, Inc.

Regulation Crowdfunding offering on Dealmaker

$6,771

of $2.64M goal

0.3% funded

About the offering

Oxeia Biopharmaceuticals is a clinical-stage biopharmaceutical company that is developing OXE-103, a ghrelin-based drug candidate intended to be the first approved treatment for concussion, in the United States.

FAQ

How much has Oxeia Biopharmaceuticals, Inc. raised?

Oxeia Biopharmaceuticals, Inc. has raised $6,771 of a $2.64M goal.

Where is Oxeia Biopharmaceuticals, Inc.'s campaign live?

The offering is live on Dealmaker, an SEC-registered Reg CF intermediary.

What are the terms of Oxeia Biopharmaceuticals, Inc.'s raise?

Preferred Stock, $50M cap, $0.79/share.

When does Oxeia Biopharmaceuticals, Inc.'s offering close?

The stated close date is Apr 25, 2027.